These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26816598)

  • 1. Renoprotective effects of incretin-based drugs: A novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor.
    Kodera R; Shikata K
    J Diabetes Investig; 2016 Jan; 7(1):29-31. PubMed ID: 26816598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism].
    Winkler G
    Orv Hetil; 2013 Feb; 154(7):248-55. PubMed ID: 23395788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 4. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 5. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Oxid Med Cell Longev; 2021; 2021():9959320. PubMed ID: 34007411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates of incretin-related drugs for the treatment of type 2 diabetes.
    Araki H; Matsumura T; Furukawa N; Araki E
    J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.
    Grunberger G
    J Diabetes; 2013 Sep; 5(3):241-53. PubMed ID: 23489968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
    Alicic RZ; Cox EJ; Neumiller JJ; Tuttle KR
    Nat Rev Nephrol; 2021 Apr; 17(4):227-244. PubMed ID: 33219281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Nangaku M; Wanner C
    Kidney Int; 2021 Feb; 99(2):318-322. PubMed ID: 33509354
    [No Abstract]   [Full Text] [Related]  

  • 11. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.
    Yaribeygi H; Atkin SL; Montecucco F; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():8163153. PubMed ID: 34471642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
    Neumiller JJ
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
    Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH
    Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The journey to understanding incretin systems: Theory, practice and more theory.
    Yabe D; Kuwata H; Seino Y
    J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incretin mimetic drugs: therapeutic positioning].
    López Simarro F
    Semergen; 2014 Jul; 40 Suppl 2():25-33. PubMed ID: 25311717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.
    Groeneveld ON; Kappelle LJ; Biessels GJ
    J Diabetes Investig; 2016 Jan; 7(1):5-16. PubMed ID: 26816596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 20. Incretin based therapies: bone protective effects.
    Chakhtoura M; Azar ST
    Endocr Metab Immune Disord Drug Targets; 2013 Dec; 13(4):289-94. PubMed ID: 24138054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.